Drug name - Carnexiv

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9629797 LUNDBECK PHARMS LLC Parenteral carbamazepine formulation Nov, 2028

(6 years from now)

US9770407 LUNDBECK PHARMS LLC Parenteral carbamazepine formulation Nov, 2028

(6 years from now)

US7635773 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US8410077 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US9750822 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US9493582 LUNDBECK PHARMS LLC Alkylated cyclodextrin compositions and processes for preparing and using the same Feb, 2033

(10 years from now)

Drugs and Companies using CARBAMAZEPINE ingredient

Treatment: Replacement therapy for oral carbamazepine in adults with partial seizures with complex symptomatology; replacement therapy for oral carbamazepine in adults with generalized tonic-clonic seizures; replacement therapy for oral carbamazepine in adults with mixed seizure patterns that include partial seizures with complex symptomatology, generalized tonic-clonic seizures, or other partial or generalized seizures

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
200MG/20ML (10MG/ML) SOLUTION;INTRAVENOUS Discontinued

availability in other generic markets.

Click on the highlighted region to filter.